Sight Sciences Receives FDA Clearance for OMNI Ultra
Menlo Park, California – August 4, 2026 Sight Sciences, Inc. has announced that the U.S. Food and Drug Administration...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Menlo Park, California – August 4, 2026 Sight Sciences, Inc. has announced that the U.S. Food and Drug Administration...
Ipswich, Massachusetts – August 4, 2026 New England Biolabs (NEB®) has expanded its molecular biology portfolio with the launch...
